Kalvista Pharmaceuticals, INC Form 4 insider transactions

Director Nancy Stuart reports the disposal of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Director Brian J.G. Pereira reports the cancellation and cash-out of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

KalVista Pharmaceuticals director William Fairey disposed of stock options following the company's acquisition by Chiesi Farmaceutici S.p.A. for $27.00 per share.

KalVista Pharmaceuticals has been acquired by Chiesi Farmaceutici in an all-cash transaction valued at $27.00 per share.

Director Bethany Sensenig reports the cancellation and cash conversion of stock options following the completed merger of KalVista Pharmaceuticals into Chiesi Farmaceutici.

Director Patrick Treanor reports the cancellation of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Chief Commercial Officer Nicole Sweeny reports the disposal of all equity holdings following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Chief Operations Officer Bilal Arif reports the disposal of equity holdings following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Director Laurence Reid reports the cancellation of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

KalVista Pharmaceuticals Director Edward W. Unkart disposed of all his stock options as part of the company's acquisition by Chiesi Farmaceutici S.p.A. for $27.00 per share.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported transactions involving stock options and restricted stock units on June 11, 2026, related to the company's merger with Chiesi Farmaceutici S.p.A.

KalVista Pharmaceuticals, Inc. announces the completion of its merger with Chiesi Farmaceutici S.p.A., with all outstanding shares acquired at $27.00 per share.

KalVista Pharmaceuticals, Inc. announced the completion of its merger with Chiesi Farmaceutici S.p.A., with all outstanding shares acquired for $27.00 per share.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported transactions involving restricted stock units and common stock sales to cover tax obligations.

Nicole Sweeny, Chief Commercial Officer at KalVista Pharmaceuticals, Inc., reported transactions involving restricted stock units and common stock.

Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals, reported transactions involving restricted stock units and common stock sales.

KalVista Pharmaceuticals, Inc. reports on insider transactions involving Chief Medical Officer Paul K. Audhya, including RSU settlement and tax withholding sales.

KalVista Pharmaceuticals' Chief Financial Officer, Brian Piekos, has reported transactions involving restricted stock units and common stock.

KalVista Pharmaceuticals Chief Development Officer Christopher Yea reported transactions involving restricted stock units and common stock.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, reported a transaction involving the sale of shares to cover tax withholding obligations.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported transactions involving restricted stock units and common stock sales to cover tax obligations.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported transactions involving restricted stock units and common stock sales to cover tax obligations.

Chief Medical Officer Paul K. Audhya acquired 6,250 shares via RSU vesting and sold 2,686 shares to cover tax obligations.

Chief Commercial Officer Nicole Sweeny acquired 6,250 shares via RSU vesting and sold 1,862 shares to cover tax obligations.

KalVista Pharmaceuticals CFO Brian Piekos acquired 6,250 shares via RSU vesting and sold 1,862 shares to cover tax obligations.

CEO Benjamin L. Palleiko acquired 20,312 shares via RSU vesting and sold 9,550 shares to cover tax obligations.

Venrock Healthcare Capital Partners and affiliated entities filed a Form 4 disclosing planned sales of over 214,000 shares of KalVista Pharmaceuticals common stock in late March 2026 under a Rule 10b5-1 plan.

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, acquired shares through RSU conversions and subsequently sold a portion to cover tax withholding obligations.

KalVista Pharmaceuticals CEO Benjamin L. Palleiko sold 10,034 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the vesting of restricted stock units and a subsequent non-discretionary sale of shares to cover tax obligations.